A team of Stanford engineers has identified first-in-class epidermal growth factor (EGF) mutants with enhanced activity. These mutants can stimulate increased EGF receptor activation at 10-fold lower concentrations than wild-type EGF.
Stanford researchers have developed a method that can tune the ratio between reversible (RE) and irreversible (IRE) electroporation through waveform adjustments.